Abraxane nab-paclitaxel: Phase III data

Top-line data from the open-label, international Phase III ETNA trial in 695 patients with HER2-negative, high-risk breast cancer showed that neoadjuvant treatment with once-weekly 125

Read the full 250 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE